Dr. Kumar on the Evolving Role of Venetoclax in Relapsed/Refractory Multiple Myeloma

Video

In Partnership With:

Shaji K. Kumar, MD, discusses the evolving role of venetoclax in relapsed/refractory multiple myeloma.

Shaji K. Kumar, MD, a consultant in the Division of Hematology and a professor of medicine with Mayo Clinic, discusses the evolving role of venetoclax (Venclexta) in relapsed/refractory multiple myeloma.

Although not FDA approved in myeloma, venetoclax has demonstrated activity in patients with relapsed/refractory disease who harbor 11;14 translocations, says Kumar. As such, single-agent venetoclax or venetoclax in combination with dexamethasone could be a valid treatment option for this subgroup of patients who have not responded to other standard combinations, Kumar explains.

Currently, venetoclax in combination with dexamethasone is being evaluated in the randomized phase 3 CANOVA trial (NCT03539744) vs pomalidomide (Pomalyst) and dexamethasone in patients with relapsed/refractory multiple myeloma, concludes Kumar.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD